April 3, 2025 11:14 AM EDT
Financing

PIPEs, bio­phar­ma’s fa­vorite fi­nanc­ing ve­hi­cle, freeze amid mar­ket strug­gles

Kyle LaHucik

Senior Reporter

PIPEs have fall­en out of fa­vor.

The pri­vate in­vest­ment in pub­lic eq­ui­ty, or PIPE, had one of the best years on record in 2024. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

FDA will con­sol­i­date to five 'shared ser­vices of­fices,' ac­cord­ing to memo to Hill staffers

Roche plans Phase 3 for its lat­est Alzheimer’s drug at­tempt af­ter un­veil­ing more ear­ly da­ta

Trump has tout­ed Right to Try as a life­saver. Sev­er­al gov­ern­ment staff sup­port­ing it were just let go

Trump’s broad tar­iffs ex­empt phar­ma — but for how long?

Chaot­ic tar­iff roll­out leaves as many ques­tions as an­swers for drug­mak­ers

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times